New prophylactics human papilloma virus (HPV) vaccines against cervical cancer

Research output: Contribution to journalReview article

Abstract

Human papillomavirus (HPV) is causatively associated with cervical cancer (CC), the fourth most common malignant disease of women worldwide. The introduction of first generation prophylactic HPV vaccines in several national vaccination programmes has substantially decreased the global incidence of HPV cervical infections. Despite the success obtained, the two-licenced bivalent and quadrivalent L1 (the major HPV capsid protein) virus-like particle (VLP)-based vaccines (2vHPV and 4vHPV) present some limitations, such as a virus-type restricted protection, the high cost of the manufacture, and an absence of therapeutic activity on the established lesions. The second-generation prophylactic HPV vaccines, constituted by alternative viral components (such as capsomere or minor capsid HPV L2 protein) or made by more cost-effective strategies of production, are undergoing an intense clinical evaluation. This review aims to offer the reader a complete and updated overview on the HPV vaccination. The authors describe the effectiveness and the limitations of the approved HPV vaccines, and highlight the main characteristics of the new generation vaccines.IMPACT STATEMENTWhat is already known on this subject? CC is the fourth most common cancer of women in the world. HPV is the etiologic cause of almost all CCs. After being approved by the FDA, the first prophylactic 2vHPV and 4vHPV have been implemented into a routine vaccination schedule around the world, substantially decreasing the incidence of HPV and related-diseases in countries with high coverage rates. Currently, research is focusing on finding innovative and alternative systems to produce and deliver new HPV vaccines, overcoming all of the limitations that have partly restricted the potential benefit of previous vaccines on public health. What do the results of this study add? This narrative review was performed to find all the published studies reporting the efficacy and limitations of 2vHPV and 4vHPV, and evaluating the new HPV vaccines under pre- and clinical investigation. What are the implications of these findings for clinical practice and/or further research? Next generation of HPV vaccines will address many, if not all, of the limitations associated with current vaccines and will represent a step forward in the fight against CC.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalJournal of Obstetrics and Gynaecology
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Papillomaviridae
Papillomavirus Vaccines
Uterine Cervical Neoplasms
Vaccination
Vaccines
Virus Diseases
Virus-Like Particle Vaccines
Costs and Cost Analysis
Viral Structures
Capsid
Incidence
Capsid Proteins
Research
Appointments and Schedules
Public Health
Viruses

Keywords

  • Cervical cancer
  • HPV vaccines
  • L1
  • L2
  • prophylactic vaccines
  • second generation vaccines

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

@article{d33eae4f0c024dcc8ebad6c77d3b1120,
title = "New prophylactics human papilloma virus (HPV) vaccines against cervical cancer",
abstract = "Human papillomavirus (HPV) is causatively associated with cervical cancer (CC), the fourth most common malignant disease of women worldwide. The introduction of first generation prophylactic HPV vaccines in several national vaccination programmes has substantially decreased the global incidence of HPV cervical infections. Despite the success obtained, the two-licenced bivalent and quadrivalent L1 (the major HPV capsid protein) virus-like particle (VLP)-based vaccines (2vHPV and 4vHPV) present some limitations, such as a virus-type restricted protection, the high cost of the manufacture, and an absence of therapeutic activity on the established lesions. The second-generation prophylactic HPV vaccines, constituted by alternative viral components (such as capsomere or minor capsid HPV L2 protein) or made by more cost-effective strategies of production, are undergoing an intense clinical evaluation. This review aims to offer the reader a complete and updated overview on the HPV vaccination. The authors describe the effectiveness and the limitations of the approved HPV vaccines, and highlight the main characteristics of the new generation vaccines.IMPACT STATEMENTWhat is already known on this subject? CC is the fourth most common cancer of women in the world. HPV is the etiologic cause of almost all CCs. After being approved by the FDA, the first prophylactic 2vHPV and 4vHPV have been implemented into a routine vaccination schedule around the world, substantially decreasing the incidence of HPV and related-diseases in countries with high coverage rates. Currently, research is focusing on finding innovative and alternative systems to produce and deliver new HPV vaccines, overcoming all of the limitations that have partly restricted the potential benefit of previous vaccines on public health. What do the results of this study add? This narrative review was performed to find all the published studies reporting the efficacy and limitations of 2vHPV and 4vHPV, and evaluating the new HPV vaccines under pre- and clinical investigation. What are the implications of these findings for clinical practice and/or further research? Next generation of HPV vaccines will address many, if not all, of the limitations associated with current vaccines and will represent a step forward in the fight against CC.",
keywords = "Cervical cancer, HPV vaccines, L1, L2, prophylactic vaccines, second generation vaccines",
author = "Fabio Barra and Maggiore, {Umberto Leone Roberti} and Giorgio Bogani and Antonino Ditto and Mauro Signorelli and Fabio Martinelli and Valentina Chiappa and Domenica Lorusso and Francesco Raspagliesi and Simone Ferrero",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/01443615.2018.1493441",
language = "English",
volume = "39",
pages = "1--10",
journal = "Journal of Obstetrics and Gynaecology",
issn = "0144-3615",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - New prophylactics human papilloma virus (HPV) vaccines against cervical cancer

AU - Barra, Fabio

AU - Maggiore, Umberto Leone Roberti

AU - Bogani, Giorgio

AU - Ditto, Antonino

AU - Signorelli, Mauro

AU - Martinelli, Fabio

AU - Chiappa, Valentina

AU - Lorusso, Domenica

AU - Raspagliesi, Francesco

AU - Ferrero, Simone

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Human papillomavirus (HPV) is causatively associated with cervical cancer (CC), the fourth most common malignant disease of women worldwide. The introduction of first generation prophylactic HPV vaccines in several national vaccination programmes has substantially decreased the global incidence of HPV cervical infections. Despite the success obtained, the two-licenced bivalent and quadrivalent L1 (the major HPV capsid protein) virus-like particle (VLP)-based vaccines (2vHPV and 4vHPV) present some limitations, such as a virus-type restricted protection, the high cost of the manufacture, and an absence of therapeutic activity on the established lesions. The second-generation prophylactic HPV vaccines, constituted by alternative viral components (such as capsomere or minor capsid HPV L2 protein) or made by more cost-effective strategies of production, are undergoing an intense clinical evaluation. This review aims to offer the reader a complete and updated overview on the HPV vaccination. The authors describe the effectiveness and the limitations of the approved HPV vaccines, and highlight the main characteristics of the new generation vaccines.IMPACT STATEMENTWhat is already known on this subject? CC is the fourth most common cancer of women in the world. HPV is the etiologic cause of almost all CCs. After being approved by the FDA, the first prophylactic 2vHPV and 4vHPV have been implemented into a routine vaccination schedule around the world, substantially decreasing the incidence of HPV and related-diseases in countries with high coverage rates. Currently, research is focusing on finding innovative and alternative systems to produce and deliver new HPV vaccines, overcoming all of the limitations that have partly restricted the potential benefit of previous vaccines on public health. What do the results of this study add? This narrative review was performed to find all the published studies reporting the efficacy and limitations of 2vHPV and 4vHPV, and evaluating the new HPV vaccines under pre- and clinical investigation. What are the implications of these findings for clinical practice and/or further research? Next generation of HPV vaccines will address many, if not all, of the limitations associated with current vaccines and will represent a step forward in the fight against CC.

AB - Human papillomavirus (HPV) is causatively associated with cervical cancer (CC), the fourth most common malignant disease of women worldwide. The introduction of first generation prophylactic HPV vaccines in several national vaccination programmes has substantially decreased the global incidence of HPV cervical infections. Despite the success obtained, the two-licenced bivalent and quadrivalent L1 (the major HPV capsid protein) virus-like particle (VLP)-based vaccines (2vHPV and 4vHPV) present some limitations, such as a virus-type restricted protection, the high cost of the manufacture, and an absence of therapeutic activity on the established lesions. The second-generation prophylactic HPV vaccines, constituted by alternative viral components (such as capsomere or minor capsid HPV L2 protein) or made by more cost-effective strategies of production, are undergoing an intense clinical evaluation. This review aims to offer the reader a complete and updated overview on the HPV vaccination. The authors describe the effectiveness and the limitations of the approved HPV vaccines, and highlight the main characteristics of the new generation vaccines.IMPACT STATEMENTWhat is already known on this subject? CC is the fourth most common cancer of women in the world. HPV is the etiologic cause of almost all CCs. After being approved by the FDA, the first prophylactic 2vHPV and 4vHPV have been implemented into a routine vaccination schedule around the world, substantially decreasing the incidence of HPV and related-diseases in countries with high coverage rates. Currently, research is focusing on finding innovative and alternative systems to produce and deliver new HPV vaccines, overcoming all of the limitations that have partly restricted the potential benefit of previous vaccines on public health. What do the results of this study add? This narrative review was performed to find all the published studies reporting the efficacy and limitations of 2vHPV and 4vHPV, and evaluating the new HPV vaccines under pre- and clinical investigation. What are the implications of these findings for clinical practice and/or further research? Next generation of HPV vaccines will address many, if not all, of the limitations associated with current vaccines and will represent a step forward in the fight against CC.

KW - Cervical cancer

KW - HPV vaccines

KW - L1

KW - L2

KW - prophylactic vaccines

KW - second generation vaccines

UR - http://www.scopus.com/inward/record.url?scp=85060543296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060543296&partnerID=8YFLogxK

U2 - 10.1080/01443615.2018.1493441

DO - 10.1080/01443615.2018.1493441

M3 - Review article

C2 - 30370796

AN - SCOPUS:85060543296

VL - 39

SP - 1

EP - 10

JO - Journal of Obstetrics and Gynaecology

JF - Journal of Obstetrics and Gynaecology

SN - 0144-3615

IS - 1

ER -